0.2318  -0.008 (-3.42%)		05-13 13:10
Open: 0.2328 High: 0.24 Volume: 254,399		Pre. Close: 0.24 Low: 0.2233 Market Cap: 15(M)

Short term
Mid term
Targets	6-month :	0.37	1-year :	0.44
Resists	First :	0.32	Second :	0.38
Pivot price	0.26
Supports	First :	0.22	Second :	0.18
MAs	MA(5) :	0.24	MA(20) :	0.29
	MA(100) :	0.52	MA(250) :	0.75
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	8.2	D(3) :	6.3
RSI	RSI(14): 26.7
52-week	High :	1.39	Low :	0.22

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ICCM ] has closed above bottom band by 8.8%. Bollinger Bands are 46.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.25 - 0.25	0.25 - 0.25
Low:	0.22 - 0.23	0.23 - 0.23
Close:	0.24 - 0.24	0.24 - 0.24

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Wed, 13 May 2026
IceCure Medical Ltd (NASDAQ:ICCM) Q1 2026 Earnings Call Transcript - Insider Monkey

Tue, 12 May 2026
ICECURE MEDICAL ($ICCM) Releases Q1 2026 Earnings - Moomoo

Tue, 12 May 2026
IceCure Medical Sets Up At-the-Market Equity Program With A.G.P./Alliance Global Partners - TipRanks

Tue, 12 May 2026
[6-K] IceCure Medical Ltd. Current Report (Foreign Issuer) | ICCM SEC Filing - Form 6-K - Stock Titan

Tue, 12 May 2026
ICCM: Strong Q1 Revenue Growth Signals Positive Market Momentum - GuruFocus

Tue, 12 May 2026
ICCM: Q1 2026 saw 26% revenue growth and accelerating U.S. adoption following FDA clearance - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	81 (M)
Shares Float	40 (M)
Held by Insiders	41.4 (%)
Held by Institutions	0.6 (%)
Shares Short	1,310 (K)
Shares Short P.Month	698 (K)

EPS	-0.24
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.11
Profit Margin	0 %
Operating Margin	-329.7 %
Return on Assets (ttm)	-71.3 %
Return on Equity (ttm)	-188.8 %
Qtrly Rev. Growth	46.2 %
Gross Profit (p.s.)	0.01
Sales Per Share	0.04
EBITDA (p.s.)	-0.19
Qtrly Earnings Growth	0 %
Operating Cash Flow	-15 (M)
Levered Free Cash Flow	-9 (M)

PE Ratio	-0.97
PEG Ratio	0
Price to Book value	1.93
Price to Sales	5.59
Price to Cash Flow	-1.3

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.